An U.S based Drug manufacturer, Compellis Pharmaceuticals, has been granted the PATENT for CP404, a nasal spray that combats obesity entitled "Inhibition of olfactory neurosensory function to treat obesity and related disorders." Compellis Pharmaceuticals is a biopharmaceutical company focusing more on developing novel mechanism-based therapeutics for treating obesity.
The company describes CP404 as "therapeutic platform for treating obesity" as it has already produced "significant weight loss" in animals. The results of the Pre-clinical animal models were published in Pharmacology, Biochemistry and Behavior.
Chris Adams, president and chief executive officer of Compellis Pharmaceuticals says that the PATENT for CP404 marks a significant milestone in the company's history as it the first issued PATENT protecting the therapeutic platform for treating obesity and also added that the company would begin human testing by 2007.
CP404 works as a calcium channel blocker, blocking the senses of smell and taste. It is taken in a nasal formulation to block olfactory activity and lessen food intake.